author-photo

Dainius Balis

Janssen Pharmaceutica

16

Papers

1155

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

2020 Ndt Plus
Show All
- Source
- Cite
- Save
Citations (5)
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

2017 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Show All
- Source
- Cite
- Save
Citations (8)
Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis

2017 Current Medical Research and Opinion
Show All
- Source
- Cite
- Save
Citations (22)
Abstract #302: Achievement of Glycemic Goals Without Hypoglycemia with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes Mellitus

2016 Endocrine Practice
Show All
- Source
- Cite
- Save
Citations (0)
Abstract #306: Canagliflozin Provides Greater Improvement in Risk Factors Associated with Metabolic Syndrome Versus Glimepiride in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome On Background Metformin

2016 Endocrine Practice
Show All
- Source
- Cite
- Save
Citations (0)
Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

2015 Diabetes Care
Show All
- Source
- Cite
- Save
Citations (178)
Iconography : Effect of canagliflozin on liver function tests in patients with type 2 diabetes

2015 Diabetes & Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净，一种钠‐葡萄糖共转运体2抑制剂，对血清1,5‐脱水葡萄糖醇测定的影响)

2014 Journal of Diabetes
Show All
- Source
- Cite
- Save
Citations (15)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

2013 The Lancet
Show All
- Source
- Cite
- Save
Citations (542)